10 August 2005
Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience
Macaulay A C Onuigbo, Nnonyelum T C OnuigboMed Sci Monit 2005; 11(10): CR462-469 :: ID: 430303
Abstract
BACKGROUND: Worsening azotemia following initiation of angiotensin blockade(AB), in patients with CKD, RAS with/without precipitating factors is recognized. Small increases inserum creatinine following initiation of AB occur and must not warrant drug discontinuation. We anecdotallyhad observed improvement in CKD in patients with normal renal arteries and no precipitating factors,following termination of AB. The worldwide ESRD epidemic, coincident with increasing use of AB, promptedus to hypothesize a late-onset azotemia in such CKD patients. MATERIAL/METHODS: Over 30 months, 103 patientswith worsening azotemia, while on AB were evaluated. Ninety-seven patients with abnormal MRA and/or withprecipitating factors were excluded. In the remaining five, AB was discontinued, and GFR monitored. RESULTS:One male, four females, mean age 66.2 years. Three diabetic/hypertensives, one SLE/hypertensive, onediabetic/kidney transplant recipient. Mean stable AB, 25.2 months, (6-66 months). Mean follow up, 11.8months. One month following discontinuation of AB, GFR increased by a mean 45%. Mean serum creatininedecreased from 2.9+/-0.9 to 1.8+/-0.4 mg/dL (p=0.04). Uremic symptoms in 3, hyperkalemia in one, secondaryhyperparathyroidism in one, resolved. Two with anemia, now require less erythropoietin. CONCLUSIONS:We called this unrecognized potentially reversible late-onset worsening azotemia, occurring several monthsto years on stable AB, in CKD patients with normal renal arteries, without precipitating factors, late-onsetrenal failure from angiotensin blockade (LORFFAB). Pathophysiologically, the concept of microvascularRAS is invoked. The extent of LORFFAB, with millions of patients worldwide on AB, remains conjecturaland warrants further investigation.
Keywords: Angiotensin II Type 1 Receptor Blockers - adverse effects, Aged, 80 and over, angiotensin receptor antagonists, Angiotensin-Converting Enzyme Inhibitors - adverse effects, Blood Pressure, Creatinine - urine, Glomerular Filtration Rate, Kidney Failure, Chronic - urine, Prospective Studies, Uremia - physiopathology, Wisconsin
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952